=> d l1
L1 HAS NO ANSWERS
L1 STR



VAR G1=O/S/N
VAR G2=1/5
VAR G3=32/35/38
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 13:04:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 94468 TO ITERATE

100.0% PROCESSED 94468 ITERATIONS 96 ANSWERS
SEARCH TIME: 00.00.01

L3 96 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	171.34	171.97

FILE 'CAPLUS' ENTERED AT 13:04:47 ON 25 MAY 2006

FILE COVERS 1907 - 25 May 2006 VOL 144 ISS 22
FILE LAST UPDATED: 24 May 2006 (20060524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 17 L3

=> d bib 1-17

L4 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1144486 CAPLUS
DN 144:51494
TI Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists
AU Xi, Ning; Bo, Yunxin; Doherty, Elizabeth M.; Fotsch, Christopher; Gavva, Narender R.; Han, Nianhe; Hungate, Randall W.; Klionsky, Lana; Liu, Qingyian; Tamir, Rami; Xu, Shimin; Treanor, James J. S.; Norman, Mark H.
CS Chemistry Research and Discovery, Amgen Inc., Thousand Oaks, CA, 91320, USA
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(23), 5211-5217
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1026876 CAPLUS
DN 143:326362
TI Preparation of substituted imidazoles as calcium ion channel modulators
IN Zelle, Robert; Galullo, Vincent P.; Baker, Christopher Todd; Will, Paul; Frazee, William J.; Mazdiyasni, Hormoz; Guo, Jinsong
PA Scion Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 430 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005086836	A2	20050922	WO 2005-US7667	20050307
	WO 2005086836	A3	20060105		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,

SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-551372P P 20040308
US 2004-551395P P 20040308
US 2004-551472P P 20040308
US 2004-551473P P 20040308
US 2004-551474P P 20040308
US 2004-551480P P 20040308
US 2004-551503P P 20040308
US 2004-551510P P 20040308
US 2004-551620P P 20040308
OS MARPAT 143:326362

L4 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:471944 CAPLUS
DN 143:26594
TI Preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette (ABC) transporters
IN Hadida Ruah, Sarah S.; Miller, Mark T.; Grootenhuis, Peter D. J.; Hamilton, Matthew
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005049018	A1	20050602	WO 2004-US38566	20041115

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005130970	A1	20050616	US 2004-989218	20041115

PRAI US 2003-520355P P 20031114
OS MARPAT 143:26594
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:470256 CAPLUS
DN 143:20052
TI Urea derivatives as kinase modulators
IN Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamal A.; Andiliy, Lai G.; Lockhart, David J.
PA Ambit Biosciences Corporation, USA
SO PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2005048948 A2 20050602 WO 2004-US38288 20041115
WO 2005048948 A3 20050728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2005148605 A1 20050707 US 2004-989745 20041115
US 2005165031 A1 20050728 US 2004-989814 20041115
US 2005165024 A1 20050728 US 2004-989824 20041115
US 2005165074 A1 20050728 US 2004-990007 20041115
US 2005171171 A1 20050804 US 2004-989766 20041115
US 2005171172 A1 20050804 US 2004-989823 20041115
US 2005192314 A1 20050901 US 2004-990195 20041115
US 2005197371 A1 20050908 US 2004-990194 20041115
US 2005261315 A1 20051124 US 2004-989623 20041115
US 2005267182 A1 20051201 US 2004-989717 20041115
PRAI US 2003-520273P P 20031113
US 2003-527094P P 20031203
US 2003-531082P P 20031218
US 2003-531243P P 20031218
OS MARPAT 143:20052

L4 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:696342 CAPLUS
DN 141:225302
TI Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists.
IN Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas; Hessler, Gerhard; Stahl, Petra; Gretzke, Dirk
PA Aventis Pharma Deutschland GmbH, Germany
SO PCT Int. Appl., 390 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004072025	A2	20040826	WO 2004-EP1342	20040213
WO 2004072025	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10306250	A1	20040909	DE 2003-10306250	20030214
AU 2004212145	A1	20040826	AU 2004-212145	20040213
CA 2516118	AA	20040826	CA 2004-2516118	20040213
EP 1597228	A2	20051123	EP 2004-710808	20040213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007504	A	20060214	BR 2004-7504	20040213
US 2004220191	A1	20041104	US 2004-779853	20040217
NO 2005004220	A	20051028	NO 2005-4220	20050912
PRAI DE 2003-10306250	A	20030214		

	US 2003-488545P	P	20030718
	WO 2004-EP1342	A	20040213

OS MARPAT 141:225302

L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:654774 CAPLUS
DN 141:190788
TI A preparation of N-containing heterocyclic compounds, useful as vanilloid receptor ligands
IN Doherty, Elizabeth M.; Fotsch, Christopher H.; Han, Nianhe; Hungate, Randall W.; Liu, Qingyian; Norman, Mark H.; Xi, Ning; Xu, Shimin
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 38 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004157845	A1	20040812	US 2004-775980	20040209
AU 2004212490	A1	20040826	AU 2004-212490	20040209
CA 2515215	AA	20040826	CA 2004-2515215	20040209
WO 2004072068	A1	20040826	WO 2004-US3908	20040209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1603905	A1	20051214	EP 2004-709532	20040209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2003-446511P	P	20030210		
WO 2004-US3908	W	20040209		

OS MARPAT 141:190788

L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:279454 CAPLUS
DN 134:295831
TI Preparation of 2-(2-alkoxy-5-heterocyclylsulfonylphenyl)purin-6-ones as phosphodiesterase inhibitors
IN Maw, Graham Nigel; Rawson, David James
PA Pfizer Limited, UK; Pfizer Inc.
SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1092718	A1	20010418	EP 2000-308644	20001002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6440982	B1	20020827	US 2000-650848	20000829
CA 2322900	AA	20010411	CA 2000-2322900	20001006
CA 2322900	C	20050208		
JP 2001114782	A2	20010424	JP 2000-310665	20001011
JP 3727525	B2	20051214		
BR 2000004786	A	20010522	BR 2000-4786	20001011
JP 2003128673	A2	20030508	JP 2002-224638	20001011
US 2003004173	A1	20030102	US 2002-189655	20020703
US 6593332	B2	20030715		

```
     US 2003013727          A1     20030116    US 2002-189680          20020703
     US 6586439             B2     20030701
PRAI GB 1999-24020          A      19991011
     US 2000-650848         A3     20000829
     JP 2000-310665         A3     20001011
OS   MARPAT 134:295831
RE.CNT  9      THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4   ANSWER 8 OF 17  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2000:98304  CAPLUS
DN   132:151564
TI   Preparation of substituted anilides as modulators, agonists or antagonists
     of the CCR5 receptor
IN   Ku, Thomas W.; Bondinell, William E.; Neeb, Michael J.
PA   Smithkline Beecham Corporation, USA
SO   PCT Int. Appl., 51 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.             KIND   DATE        APPLICATION NO.         DATE
     ---------------        ----   --------    --------------------    --------
PI   WO 2000006146           A1     20000210    WO 1999-US17121         19990728
         W:  AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX,
             NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2338764             AA     20000210    CA 1999-2338764         19990728
     AU 9952392             A1     20000221    AU 1999-52392           19990728
     BR 9912406             A      20010424    BR 1999-12406           19990728
     EP 1100485             A1     20010523    EP 1999-937589          19990728
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     TR 200100267           T2     20010921    TR 2001-200100267       19990728
     JP 2002521436          T2     20020716    JP 2000-562001          19990728
     NO 2001000446          A      20010126    NO 2001-446             20010126
PRAI US 1998-94406P         P      19980728
     US 1999-134157P        P      19990514
     WO 1999-US17121        W      19990728
OS   MARPAT 132:151564
RE.CNT  1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4   ANSWER 9 OF 17  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   1999:495272  CAPLUS
DN   131:130011
TI   Preparation of N-acyl-2-aminoacetamides and cyclization products thereof.
IN   Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere,
     Richard F.; Mason, Helen J.; Morrissette, Matthew M.; Ma, Liang; Cherrier,
     Marie-Pierre
PA   Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SO   PCT Int. Appl., 156 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.             KIND   DATE        APPLICATION NO.         DATE
     ---------------        ----   --------    --------------------    --------
PI   WO 9938844             A1     19990805    WO 1999-US1923          19990129
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK,
```

EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	CA 2318601	AA	19990805	CA 1999-2318601	19990129
	AU 9924821	A1	19990816	AU 1999-24821	19990129
	AU 747987	B2	20020530		
	ZA 9900729	A	20000110	ZA 1999-729	19990129
	EP 1051397	A1	20001115	EP 1999-904421	19990129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	BR 9908207	A	20001128	BR 1999-8207	19990129
	JP 2002501944	T2	20020122	JP 2000-530081	19990129
	AP 1462	A	20050930	AP 2000-200001864	19990129
	W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
	US 6492553	B1	20021210	US 1999-368213	19990804
	NO 2000003792	A	20000927	NO 2000-3792	20000724
	BG 104724	A	20010330	BG 2000-104724	20000829
PRAI	US 1998-73007P	A2	19980129		
	US 1998-98404P	A2	19980831		
	US 1998-98708P	A2	19980901		
	US 1998-101056P	A2	19980918		
	WO 1999-US1923	W	19990129		

OS MARPAT 131:130011
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:816534 CAPLUS
DN 130:110257
TI Preparation of thiazole derivatives and their pharmaceutical uses
IN Sugihara, Yoshihiro; Uchibayashi, Naoto; Maezaki, Hironobu; Nozaki, Yukimasa; Ichimori, Yuzo; Ii, Masayuki
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10338680	A2	19981222	JP 1997-149739	19970606
PRAI	JP 1997-149739		19970606		

OS MARPAT 130:110257

L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:323346 CAPLUS
DN 120:323346
TI Ring chain transformations. XII. Synthesis of N-(3-aminothioacryloyl)lactam imines and their transformation to 4-(ω-amino-alkyl)thiazoles or N-(thien-2-yl)lactam imines
AU Paetzel, Michael; Knoll, Alexander; Steinke, Thomas; von Loewis, Michael; Liebscher, Juergen
CS Fachbereich Chem., Humboldt-Univ., Berlin, Germany
SO Journal fuer Praktische Chemie/Chemiker-Zeitung (1993), 335(7), 639-43
CODEN: JPCCEM; ISSN: 0941-1216
DT Journal
LA English

L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:135271 CAPLUS

DN 110:135271
TI Preparation of imidazothiadiazines as hypotensives and vasodilators
IN Ohsaki, Tsutomu; Sakakibara, Jinsaku; Kuriki, Takeo
PA Hoechst Japan Ltd., Japan
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 286041	A1	19881012	EP 1988-105347	19880402
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 01025786	A2	19890127	JP 1987-209066	19870821
	JP 2552494	B2	19961113		
	US 4942143	A	19900717	US 1988-178231	19880406
	DK 8801894	A	19881009	DK 1988-1894	19880407
PRAI	JP 1987-86130	A	19870408		
	JP 1987-209066	A	19870821		

OS CASREACT 110:135271; MARPAT 110:135271

L4 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:38935 CAPLUS
DN 110:38935
TI Reactions of mesoionic five-membered heterocycles with o-quinoid compounds. VII. Thermal [π4 + π4]cycloadditions of a bicyclic imidazolo[1,2-c]thiazole system
AU Friedrichsen, Willy; Koenig, B. Michael; Debaerdemaeker, Tony
CS Inst. Org. Chem., Univ. Kiel, Kiel, D-2300, Fed. Rep. Ger.
SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1988), 43(3), 347-60
CODEN: ZNBSEN; ISSN: 0932-0776
DT Journal
LA German
OS CASREACT 110:38935

L4 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1983:405563 CAPLUS
DN 99:5563
TI Nitroimidazoles: Part XVII. 5-Aminoimidazoles
AU Sudarsanam, V.; Nagarajan, K.; Gokhale, N. G.
CS Ciba-Geigy Res. Cent., Bombay, 400 063, India
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1982), 21B(12), 1087-91
CODEN: IJSBDB; ISSN: 0376-4699
DT Journal
LA English
OS CASREACT 99:5563

L4 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1974:515750 CAPLUS
DN 81:115750
TI Systemic and chemotherapeutic fungicidal activity-chemical structure relation of some 4-methyl-5-thiazolecarboxylic acid derivatives. Laboratory screening tests
AU Abdel-Lateef, Mahmoud F. A.; Stec, Maria; Eckstein, Zygmunt
CS Fac. Agric., Al-Azhar Univ., Cairo, Egypt
SO Acta Phytopathologica Academiae Scientiarum Hungaricae (1973), 8(3-4), 269-82
CODEN: APYPBZ; ISSN: 0001-6780
DT Journal
LA English

L4 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1973:147941 CAPLUS
DN 78:147941
TI Thiazole-5-carboxanilide hydrochlorides
IN Girgis, Mikhail Milad
PA Uniroyal Ltd.
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2242471	A1	19730308	DE 1972-2242471	19720829
	US 3794636	A	19740226	US 1971-177822	19710903
	CA 970779	A1	19750708	CA 1972-148093	19720727
	GB 1401680	A	19750730	GB 1972-40027	19720829
	FR 2152056	A5	19730420	FR 1972-31134	19720901
	NL 7211992	A	19730306	NL 1972-11992	19720902
	IT 968312	A	19740320	IT 1972-69805	19720902
	JP 48039477	A2	19730609	JP 1972-88608	19720904
PRAI	US 1971-177822	A	19710903		

L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1963:53202 CAPLUS
DN 58:53202
OREF 58:9040e-h
TI Compounds with potential antitubercular activity. IV. N-Substituted thioamides of 4-Oxazolecarboxylic acids
AU Sycheva, T. P.; Trupp, T. Kh.; Shchukina, M. N.
CS S. Ordzhonikidze All-Union Chem.-Pharm. Research Inst., Moscow
SO Zhurnal Obshchei Khimii (1962), 32, 2882-5
CODEN: ZOKHA4; ISSN: 0044-460X
DT Journal
LA Unavailable

AN 1963:53202 CAPLUS
DN 58:53202
OREF 58:9040e-h
TI Compounds with potential antitubercular activity. IV. N-Substituted thioamides of 4-Oxazolecarboxylic acids
AU Sycheva, T. P.; Trupp, T. Kh.; Shchukina, M. N.
CS S. Ordzhonikidze All-Union Chem.-Pharm. Research Inst., Moscow
SO Zhurnal Obshchei Khimii (1962), 32, 2882-5
CODEN: ZOKHA4; ISSN: 0044-460X
DT Journal
LA Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. CA 58, 1448h. Addition of 6.9 g. POCl3 to 3.81 g. 2-methyl-4-oxazolecarboxylic acid and 2.79 g. PhNH2 and heating 1 hr. at 130° gave after an aqueous treatment 8.9 g. 2-methyl-4-oxazolecarboxanilide (I, R = Me) (II), m. 133.5-5.5°. Similarly were prepared the following I (R given): PhCH2, m. 109.5-11°; Ph, m. 187-9°; p-MeC6H4, m. 180.5-2.5% Similarly were prepared: 2-benzyl-4-oxazolecarbomoypholide, m. 108-10% and the corresponding p-toluidide, m. 121-2°. II (1 g.) in 25 ml. pyridine heated with 2 g. P2S5 at 120-30° (bath temperature) 4 hrs. gave after an aqueous treatment and extraction of the precipitate with hot MeOH, 0.25 g. yellow 2-methyl-4-oxazolecarbothioanilide (III), m. 123-5°. Similarly were prepared the III analogs with following 2-substituents: PhCH2, m. 111-:3.5; Ph, m. 104-5°. Similarly were prepared 2-benzyl-4-oxazolecarbothio-p-toluidide, m. 91-3°, and the analogous thiomorpholide, m. 94-6°. 2-p-Tolyl-4-oxazolecarboxanilide and P2S5 in pyridine 10 hrs. at 120-30° gave after an aqueous treatment yellow 2-p-tolyl-4-thiazolecarbothioanilide, m. 147-9°. Et 2-p-tolyl4-oxazolecarboxylate in 2N NaOH 1 hr. gave the free acid, decomposed 229-30°. The replacement of the hetero O atom by S in the reaction with P2S5 was not observed for the other examples above.
IT **93323-65-0**, 4-Oxazolecarboxanilide, 2-benzyl- **98511-88-7**, 4-Oxazolecarboxy-p-toluidide, 2-benzyl-
(preparation of)
RN 93323-65-0 CAPLUS
CN 4-Oxazolecarboxanilide, 2-benzyl- (7CI) (CA INDEX NAME)



RN 98511-88-7 CAPLUS
CN 4-Oxazolecarboxy-p-toluidide, 2-benzyl- (7CI) (CA INDEX NAME)



```
=> s l4 and vanilloid
          1459 VANILLOID
L5           2 L4 AND VANILLOID

=> d bib 1-2

L5   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:1144486  CAPLUS
DN   144:51494
TI   Synthesis and evaluation of thiazole carboxamides as vanilloid
     receptor 1 (TRPV1) antagonists
AU   Xi, Ning; Bo, Yunxin; Doherty, Elizabeth M.; Fotsch, Christopher; Gavva,
     Narender R.; Han, Nianhe; Hungate, Randall W.; Klionsky, Lana; Liu,
     Qingyian; Tamir, Rami; Xu, Shimin; Treanor, James J. S.; Norman, Mark H.
CS   Chemistry Research and Discovery, Amgen Inc., Thousand Oaks, CA, 91320,
     USA
SO   Bioorganic & Medicinal Chemistry Letters (2005), 15(23), 5211-5217
     CODEN: BMCLE8; ISSN: 0960-894X
PB   Elsevier B.V.
DT   Journal
LA   English
RE.CNT  23    THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:654774  CAPLUS
DN   141:190788
TI   A preparation of N-containing heterocyclic compounds, useful as
     vanilloid receptor ligands
IN   Doherty, Elizabeth M.; Fotsch, Christopher H.; Han, Nianhe; Hungate,
     Randall W.; Liu, Qingyian; Norman, Mark H.; Xi, Ning; Xu, Shimin
PA   Amgen Inc., USA
SO   U.S. Pat. Appl. Publ., 38 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   US 2004157845        A1    20040812    US 2004-775980          20040209
     AU 2004212490        A1    20040826    AU 2004-212490          20040209
     CA 2515215           AA    20040826    CA 2004-2515215         20040209
     WO 2004072068        A1    20040826    WO 2004-US3908          20040209
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
             BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
             MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1603905           A1    20051214    EP 2004-709532          20040209
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2003-446511P      P     20030210
     WO 2004-US3908       W     20040209
OS   MARPAT 141:190788


=> s l4 not l5
L6           15 L4 NOT L5
```

=> d bib abs hitstr 1-15

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1026876 CAPLUS
DN 143:326362
TI Preparation of substituted imidazoles as calcium ion channel modulators
IN Zelle, Robert; Galullo, Vincent P.; Baker, Christopher Todd; Will, Paul; Frazee, William J.; Mazdiyasni, Hormoz; Guo, Jinsong
PA Scion Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 430 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005086836	A2	20050922	WO 2005-US7667	20050307
	WO 2005086836	A3	20060105		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 2004-551372P	P	20040308
	US 2004-551395P	P	20040308
	US 2004-551472P	P	20040308
	US 2004-551473P	P	20040308
	US 2004-551474P	P	20040308
	US 2004-551480P	P	20040308
	US 2004-551503P	P	20040308
	US 2004-551510P	P	20040308
	US 2004-551620P	P	20040308

OS MARPAT 143:326362
GI



I



II

AB The title imidazoles such as I [Ar1 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl; X = NR3, C(R3)2, O; Y = C(O), alkylene; R1 = Ar2, alkyl optionally substituted with Ar2 (wherein Ar2 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl); q = 0-2; R2 = (CH2)mCO2R3, (CH2)mC(O)Ar3, (CH2)mAr3, etc. (R3 = H, alkyl; m = 1-2; Ar3 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl)] which can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets, were prepared E.g., a multi-step synthesis of II, starting from p-toluidine, was given. Oocyte assays, HEK assays, and formalin tests were carried out (no data given).

IT **865079-41-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted imidazoles as calcium ion channel modulators)

RN 865079-41-0 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-N-(4-fluorophenyl)-2-[(4-fluorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:471944 CAPLUS

DN 143:26594

TI Preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette (ABC) transporters

IN Hadida Ruah, Sarah S.; Miller, Mark T.; Grootenhuis, Peter D. J.; Hamilton, Matthew

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005049018	A1	20050602	WO 2004-US38566	20041115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005130970	A1	20050616	US 2004-989218	20041115

PRAI US 2003-520355P P 20031114
OS MARPAT 143:26594
GI



I

AB A method of modulating ABC transporter activity comprises administration of title compds. [I; X = O, S; R1 = H, 3-8 membered (substituted) (unsatd.) (heterocyclic) ring; Z = bond, (substituted) (heteroatom-interrupted) alkylidene; R2 = halo, CF3, cyano, NO2, TqR; R3 = UmR'; R4 = VpCy1; m, p, q = 0, 1; U, V, T = (substituted) (heteroatom-interrupted) alkylidene; Cy1 = 3-8 membered (substituted) (unsatd.) (heterocyclic) ring; R = H, (substituted) aliphatyl; R' = R, (substituted) (unsatd.) (heterocyclic) ring]. Thus, 2-(4-methoxybenzyl)thiazole-4-carboxylic acid, C-[1-(3,4-dimethoxyphenyl)cyclopentyl]methylamine (preparation given), Et3N, and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate were stirred together for 16 h in MeCN to give 43.9% 2-(4-methoxybenzyl)thiazole-4-carboxylic acid [1-(3,4-dimethoxyphenyl)cyclopentyl]methylamide. Some I exhibit a relative modulating efficacy of >30%.

IT **852639-06-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters)

RN 852639-06-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)methyl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:470256 CAPLUS
DN 143:20052
TI Urea derivatives as kinase modulators
IN Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamal A.; Andiliy, Lai G.; Lockhart, David J.
PA Ambit Biosciences Corporation, USA
SO PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005048948	A2	20050602	WO 2004-US38288	20041115
	WO 2005048948	A3	20050728		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005148605	A1	20050707	US 2004-989745	20041115
	US 2005165031	A1	20050728	US 2004-989814	20041115
	US 2005165024	A1	20050728	US 2004-989824	20041115
	US 2005165074	A1	20050728	US 2004-990007	20041115
	US 2005171171	A1	20050804	US 2004-989766	20041115
	US 2005171172	A1	20050804	US 2004-989823	20041115
	US 2005192314	A1	20050901	US 2004-990195	20041115
	US 2005197371	A1	20050908	US 2004-990194	20041115
	US 2005261315	A1	20051124	US 2004-989623	20041115
	US 2005267182	A1	20051201	US 2004-989717	20041115
PRAI	US 2003-520273P	P	20031113		
	US 2003-527094P	P	20031203		
	US 2003-531082P	P	20031218		
	US 2003-531243P	P	20031218		

OS MARPAT 143:20052

AB The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of urea compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects such as cellular proliferative disorders.

IT **852671-22-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(urea derivs. as kinase modulators for treatment of cellular proliferative disorders)

RN 852671-22-8 CAPLUS

CN 4-Thiazolecarboxamide, N-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]-2-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:696342 CAPLUS
DN 141:225302
TI Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists.

IN Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas; Hessler, Gerhard; Stahl, Petra; Gretzke, Dirk

PA Aventis Pharma Deutschland GmbH, Germany

SO PCT Int. Appl., 390 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004072025	A2	20040826	WO 2004-EP1342	20040213
	WO 2004072025	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10306250	A1	20040909	DE 2003-10306250	20030214
	AU 2004212145	A1	20040826	AU 2004-212145	20040213
	CA 2516118	AA	20040826	CA 2004-2516118	20040213
	EP 1597228	A2	20051123	EP 2004-710808	20040213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007504	A	20060214	BR 2004-7504	20040213
	US 2004220191	A1	20041104	US 2004-779853	20040217
	NO 2005004220	A	20051028	NO 2005-4220	20050912
PRAI	DE 2003-10306250	A	20030214		
	US 2003-488545P	P	20030718		
	WO 2004-EP1342	A	20040213		

OS MARPAT 141:225302

GI



I

AB Title compds. [I; R1, R2 = H, alkyl, alkoxyalkyl, aryloxyalkyl, alkylcarbonyl, alkenylcarbonyl, etc.; R1R2N = atoms to form a 4-10 membered mono-, bi-, or spirocyclic (substituted) ring; R3 = H, alkyl; R4, R5 = H, alkyl, OH, alkoxy, alkylcarbonyloxy, alkylthio; R6-R9 = H, alkyl; R6R7, R8R9 = O; A, B, D, G = N, CR42; AB, DG = CR42; R42 = H, F, Cl, Br, iodo, CF3, NO2, cyano, OCF3, alkoxy, alkylthio, alkenyl, cycloalkyl, cycloalkoxy, cycloalkenyl, alkynyl, CO2H, etc.; R10 = H, alkyl, alkenyl, alkynyl; X = NR52, O, bond, C:C, C.tplbond.C, etc.; R52 = H, alkyl; E = (substituted) C3-14 carbocyclyl, heterocyclyl; K = bond, O, CH2O, S, SO, CO, C:C, C.tplbond.C, etc.; R11 = H, alkyl, alkoxyalkyl, alkenyl, alkynyl, 3-10 membered (substituted) mono-, bi-, tri- or spirocyclic ring; EKR11 = (unsatd.) tricyclic ring; m, n = 0-2], were prepared Thus, N-[1-(4-aminophenyl)pyrrolidin-3-yl]piperidine was treated with carbonyldiimidazole and then with 4-(4-chlorophenyl)piperidine to give 4-(4-chlorophenyl)piperidine-1-carboxylic acid [4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl]amide. The latter at 30 mg/kg

orally in female NMRI mice reduced milk consumption by 64%.

IT **748175-48-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-arylheterocycles as MCH antagonists)

RN 748175-48-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-2-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:279454 CAPLUS

DN 134:295831

TI Preparation of 2-(2-alkoxy-5-heterocyclylsulfonylphenyl)purin-6-ones as phosphodiesterase inhibitors

IN Maw, Graham Nigel; Rawson, David James

PA Pfizer Limited, UK; Pfizer Inc.

SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1092718	A1	20010418	EP 2000-308644	20001002
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6440982	B1	20020827	US 2000-650848	20000829
	CA 2322900	AA	20010411	CA 2000-2322900	20001006
	CA 2322900	C	20050208		
	JP 2001114782	A2	20010424	JP 2000-310665	20001011
	JP 3727525	B2	20051214		
	BR 2000004786	A	20010522	BR 2000-4786	20001011
	JP 2003128673	A2	20030508	JP 2002-224638	20001011
	US 2003004173	A1	20030102	US 2002-189655	20020703
	US 6593332	B2	20030715		
	US 2003013727	A1	20030116	US 2002-189680	20020703
	US 6586439	B2	20030701		
PRAI	GB 1999-24020	A	19991011		
	US 2000-650848	A3	20000829		
	JP 2000-310665	A3	20001011		

OS MARPAT 134:295831

GI



I



II

AB The title compds. [I or II; X = CH, N; R1 = H, CN, aryl, etc.; R2 = H, aryl, alkyl, etc.; R3 = H, (un)substituted alkyl; Het1 = 4-12 membered heterocyclyl which contains at least one N atom and, optionally, one or more further heteroatoms selected from N, O, and/or S], useful in the curative and prophylactic treatment of medical conditions for which inhibition of a cyclic guanosine 3',5'-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired (such as male erectile dysfunction), were prepared and formulated. E.g., 3-step synthesis of II [X = CH; R1 = H; R2, R3 = Pr; Het1 = 4-(pyridin-2-yl)piperazin-1-yl] which showed 100% PDE5 inhibition at 10 nM, was given.

IT **334497-15-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-(2-alkoxy-5-heterocyclylsulfonylphenyl)purin-6-ones as phosphodiesterase inhibitors)

RN 334497-15-3 CAPLUS

CN 1H-Imidazole-4-carboxamide, 5-[(2-ethoxybenzoyl)amino]-2-(phenylmethyl)-1-propyl- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:98304 CAPLUS
DN 132:151564
TI Preparation of substituted anilides as modulators, agonists or antagonists of the CCR5 receptor
IN Ku, Thomas W.; Bondinell, William E.; Neeb, Michael J.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000006146	A1	20000210	WO 1999-US17121	19990728

W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU,

ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX,
NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	CA 2338764	AA	20000210	CA 1999-2338764	19990728
	AU 9952392	A1	20000221	AU 1999-52392	19990728
	BR 9912406	A	20010424	BR 1999-12406	19990728
	EP 1100485	A1	20010523	EP 1999-937589	19990728
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200100267	T2	20010921	TR 2001-200100267	19990728
	JP 2002521436	T2	20020716	JP 2000-562001	19990728
	NO 2001000446	A	20010126	NO 2001-446	20010126
PRAI	US 1998-94406P	P	19980728		
	US 1999-134157P	P	19990514		
	WO 1999-US17121	W	19990728		

OS MARPAT 132:151564

GI



I



II

AB The title compds. [I; the basic N in moiety E may be optionally quaternized with alkyl or is optionally present as the N-oxide; P1, P2 = Ph, fused bicyclic aryl, monocyclic heterocyclyl, etc.; A = CO, O, SOc, etc.; L = CH2NH, NHCH2, etc.; R1, R2 = H, alkyl, alkenyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; a, b = 1-3; c = 0-2] which are modulators, agonists or antagonists of the CCR5 receptor, and therefore useful in treating COPD, asthma and atopic disorders, rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, and HIV, were prepared E.g., a synthesis of benzamide II starting with (4-formyl-3,5-dimethoxyphenoxy)-Merrifield resin and 3-[2-(diethylamino)ethoxy]-4-methoxyaniline, was given. Compds. I show CCR5 receptor modulator activity having IC50 values of 0.0001 to 100 μM.

IT **257616-35-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted anilides as modulators, agonists or antagonists of the CCR5 receptor)

RN 257616-35-6 CAPLUS
CN 4-Thiazolecarboxamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:495272 CAPLUS
DN 131:130011
TI Preparation of N-acyl-2-aminoacetamides and cyclization products thereof.
IN Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere, Richard F.; Mason, Helen J.; Morrissette, Matthew M.; Ma, Liang; Cherrier, Marie-Pierre
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SO PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938844	A1	19990805	WO 1999-US1923	19990129
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2318601	AA	19990805	CA 1999-2318601	19990129
	AU 9924821	A1	19990816	AU 1999-24821	19990129
	AU 747987	B2	20020530		
	ZA 9900729	A	20000110	ZA 1999-729	19990129
	EP 1051397	A1	20001115	EP 1999-904421	19990129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	BR 9908207	A	20001128	BR 1999-8207	19990129
	JP 2002501944	T2	20020122	JP 2000-530081	19990129
	AP 1462	A	20050930	AP 2000-200001864	19990129
	W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
	US 6492553	B1	20021210	US 1999-368213	19990804
	NO 2000003792	A	20000927	NO 2000-3792	20000724
	BG 104724	A	20010330	BG 2000-104724	20000829
PRAI	US 1998-73007P	A2	19980129		
	US 1998-98404P	A2	19980831		
	US 1998-98708P	A2	19980901		
	US 1998-101056P	A2	19980918		
	WO 1999-US1923	W	19990129		

OS MARPAT 131:130011
AB RaRbNCRcaRcbRd Ra = RaaCO; Dd = CONHRda; Raa, Rb, Rca, Rcb = H, (substituted) aliphatyl, aryl; Rda = (substituted) aliphatyl, aryl; with provisos were prepared by reaction of RcaCORcb with RbNH2, RaCO2H, and NCRda. Title compds. may be prepared on a isocyanide resin and deprotected/cyclized to give 1,4-benzodiazepine-2,5-diones, diketopiperazines, ketopiperazines, lactams, 1,4-benzodiazapines, and dihydroquinoxalinones.
IT **234781-43-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of N-acyl-2-aminoacetamides and cyclization products thereof)
RN 234781-43-2 CAPLUS
CN 1H-Imidazole-5-carboxamide, 2-(diphenylmethyl)-4,5-dihydro-N-phenyl-4-[[4-(phenylmethoxy)phenyl]methyl]-1-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:816534 CAPLUS
DN 130:110257
TI Preparation of thiazole derivatives and their pharmaceutical uses
IN Sugihara, Yoshihiro; Uchibayashi, Naoto; Maezaki, Hironobu; Nozaki, Yukimasa; Ichimori, Yuzo; Ii, Masayuki
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10338680	A2	19981222	JP 1997-149739	19970606
PRAI JP 1997-149739		19970606		

OS MARPAT 130:110257
GI



I

AB The derivs. I [R1 = (un)substituted hydrocarbyl, (un)substituted heterocyclyl, (un)substituted amino; n = 1, 2; R2 = cyano, (un)substituted acyl, (un)substituted (thio)carbamoyl, (un)esterified carboxy, (un)substituted vinyl, (un)substituted ethynyl, (un)substituted amidino, (un)substituted halomethyl; R3 = group linked via C; if R2 = CO2Et, then R1 = (un)substituted hydrocarbyl, (un)substituted heterocyclyl] or their salts are prepared NO formation inhibitors and interleukin 6 inhibitors containing I or their salts are also claimed. I and their salts are useful

for prevention and treatment of heart diseases, autoimmune diseases, inflammatory diseases, and granulomatous diseases, etc. A toluene solution of 3,3-bis(methylthio)-2-N-triphenylphosphoranylideneaminoacrylonitrile (preparation given) was treated with BzCl under reflux for 4 h and the resulting product was oxidized with m-ClC6H4CO3H at room temperature for 1 h to give 2-phenyl-5-methylsulfonyl-4-thiazolecarbonitrile. This inhibited interferon γ-induced NO formation by RAW264.7 cell at IC50 0.023 μM.

IT **219623-66-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazole derivs. as NO synthesis inhibitors and IL-6 inhibitors, and their pharmaceutical uses)

RN 219623-66-2 CAPLUS
CN 4-Thiazolecarboxamide, N-ethyl-5-methyl-N-phenyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:323346 CAPLUS
DN 120:323346
TI Ring chain transformations. XII. Synthesis of N-(3-aminothioacryloyl)lactam imines and their transformation to 4-(ω-amino-alkyl)thiazoles or N-(thien-2-yl)lactam imines
AU Paetzel, Michael; Knoll, Alexander; Steinke, Thomas; von Loewis, Michael; Liebscher, Juergen
CS Fachbereich Chem., Humboldt-Univ., Berlin, Germany
SO Journal fuer Praktische Chemie/Chemiker-Zeitung (1993), 335(7), 639-43
CODEN: JPCCEM; ISSN: 0941-1216
DT Journal
LA English
GI



I



II



III



IV

AB 3-Aminothioacrylamides R2NCH:CR1CSNH2 (R2N = piperidino, pyrrolidino, morpholino Me2N; R1 = Ph, 4-ClC6H4, cyano) reacts with lactam acetals I (n = 1, 2, 3) to give the (aminothioacryloyl)lactam imines II. II reacted with R2CH2X (R2 = 4-bromobenzoyl, NO2, 5-nitro-2-furyl, etc.; X = halo) to give the N-(thien-2-yl)lactam imines III and 4-(ω-amino-alkyl)thiazoles IV. The MNDO calcns. of semicyclic aza(chlorobenzyl)pentamethinium intermediates was discussed.

IT **155243-66-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 155243-66-6 CAPLUS

CN 4-Thiazolepentanamine, 5-(1H-benzimidazol-2-yl)-2-[1-(4-chlorophenyl)-2-(1-piperidinyl)ethenyl]-N-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:135271 CAPLUS

DN 110:135271

TI Preparation of imidazothiadiazines as hypotensives and vasodilators

IN Ohsaki, Tsutomu; Sakakibara, Jinsaku; Kuriki, Takeo

PA Hoechst Japan Ltd., Japan

SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 286041	A1	19881012	EP 1988-105347	19880402
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 01025786	A2	19890127	JP 1987-209066	19870821
	JP 2552494	B2	19961113		
	US 4942143	A	19900717	US 1988-178231	19880406
	DK 8801894	A	19881009	DK 1988-1894	19880407
PRAI	JP 1987-86130	A	19870408		
	JP 1987-209066	A	19870821		

OS CASREACT 110:135271; MARPAT 110:135271

GI



I



II

AB Title compds. I [R1,R2,R4 = alkyl, aryl, aralkyl (which groups may have ≥1 substituents); R3 = H, halo, alkyl, aryl, aralkyl (which groups may have ≥1 substituents)], useful as hypotensives and vasodilators (no data), are prepared by cyclocondensation of imidazoles II [R5 H, alkyl, aryl, aralkyl which groups may have ≥1 substituents)] with a thionyl halide in the presence of a tertiary amine, and optionally reacting the resulting product with a halogenating agent. A mixture of hexyltheobromine and 3N NaOH was refluxed for 6 h to give 38% II (R2 = hexyl; R2 = R4 = Me; R5 = H), to which SOCl2 in pyridine was added and the mixture was stirred at ambient temperature for 3 h to afford 64% I (R1 = R4 = Me, R2 = hexyl, R3 = H).

IT **119229-81-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of imidazothiadiazine hypotensives and vasodilators)

RN 119229-81-1 CAPLUS

CN 1H-Imidazole-5-carboxamide, N-phenyl-4-(phenylamino)-2-(phenylmethyl)-1-propyl- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:38935 CAPLUS

DN 110:38935

TI Reactions of mesoionic five-membered heterocycles with o-quinoid compounds. VII. Thermal [π4 + π4]cycloadditions of a bicyclic imidazolo[1,2-c]thiazole system

AU Friedrichsen, Willy; Koenig, B. Michael; Debaerdemaeker, Tony

CS Inst. Org. Chem., Univ. Kiel, Kiel, D-2300, Fed. Rep. Ger.

SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1988), 43(3), 347-60
CODEN: ZNBSEN; ISSN: 0932-0776

DT Journal

LA German

OS CASREACT 110:38935

GI



II



III

AB 5-(4-Methylphenyl)-2,7-diphenyl-4-phenylcarbamoylimidazolo[1,2-c]thiazole reacts with tetrachloro-o-benzoquinone to give a [π4 + π4]cycloadduct (I). In an obviously analogous manner 5-(4-methylphenyl)-2,7-diphenylmidazolo[1,2-c]thiazoloe reacts with N,N'-benzenesulfonyl-o-benzoquinonediimine to give adduct II. I solvolyzes with alcs. in a stereoselective SN2'' reaction giving imidazothiazoles III (R = Me, CHMe2). The stereochem. outcome of this reaction has been determined by an x-ray anal. of III (R = Me).

IT **117034-92-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 117034-92-1 CAPLUS

CN 1H-Imidazole-4-carboxamide, 2-benzoyl-5-(4-methylphenyl)-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1983:405563 CAPLUS

DN 99:5563

TI Nitroimidazoles: Part XVII. 5-Aminoimidazoles

AU Sudarsanam, V.; Nagarajan, K.; Gokhale, N. G.

CS Ciba-Geigy Res. Cent., Bombay, 400 063, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1982), 21B(12), 1087-91
CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 99:5563

GI



I



II



III



IV

AB 2-Benzoyl-1-methyl-5-nitroimidazole I (R = H) undergoes reduction over Raney nickel catalyst to the amine, which is transformed into II (R1 = p-ClC6H4CO, EtO2CNHCS, p-MeC6H4SO3NHCS, PhCONHCS). Hydrogenation of the I (R = NO2) and condensation of the product with DMF dimethyl acetal leads to a bis-amidine. Catalytic reduction of the nitrosulfone III (R2 = NO2) affords unstable III (R2 = NH2) which was converted into stable N-acyl derivs. and thioureas. Reaction of III (R2 = NH2) with p-O2NC6H4CHO furnishes in low yield an anomalous product considered to be IV which probably results via the benzylidene-bisimidazole and the tricyclic condensed pyridines. 2-Methylsulfonyl-1-methyl-5-aminoimidazole arising from the nitro derivative is characterized as the acylthioureas. Likewise the reduction product of 1-methylsulfonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone was isolated as the acetylamino derivative

IT **86008-39-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 86008-39-1 CAPLUS

CN Benzamide, N-(2-benzoyl-1-methyl-1H-imidazol-5-yl)-4-chloro- (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:515750 CAPLUS

DN 81:115750

TI Systemic and chemotherapeutic fungicidal activity-chemical structure relation of some 4-methyl-5-thiazolecarboxylic acid derivatives. Laboratory screening tests

AU Abdel-Lateef, Mahmoud F. A.; Stec, Maria; Eckstein, Zygmunt

CS Fac. Agric., Al-Azhar Univ., Cairo, Egypt

SO Acta Phytopathologica Academiae Scientiarum Hungaricae (1973), 8(3-4), 269-82
CODEN: APYPBZ; ISSN: 0001-6780

DT Journal

LA English

AB Of 137 synthetic 4-methyl-5-thiazolecarboxylates (I, X = H, halo, Me, SH, alkoxy, aryloxy, alkylthio, arylthio, aryloxyalkyl heterocyclic radical, etc. R = HO, alkoxy, substituted amine, etc) 108 were previously undescribed. I compds. were screened with Alternaia tenuis, Phytophthora infestans, Rhizoctonia, solani, Tilletia caries, and Venturia inaequalis for chemical structure-activity relations. The m.p., yield, and fungicidal activities of I compds. are tabulated, and their structure-activity relations are discussed.

IT **53040-09-8P 53040-10-1P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and fungicidal activity of)

RN 53040-09-8 CAPLUS
CN 5-Thiazolecarboxamide, 4-methyl-N-phenyl-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 53040-10-1 CAPLUS
CN 5-Thiazolecarboxamide, 2-(diphenylmethyl)-4-methyl-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1973:147941 CAPLUS
DN 78:147941
TI Thiazole-5-carboxanilide hydrochlorides
IN Girgis, Mikhail Milad
PA Uniroyal Ltd.
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2242471	A1	19730308	DE 1972-2242471	19720829
	US 3794636	A	19740226	US 1971-177822	19710903
	CA 970779	A1	19750708	CA 1972-148093	19720727
	GB 1401680	A	19750730	GB 1972-40027	19720829
	FR 2152056	A5	19730420	FR 1972-31134	19720901
	NL 7211992	A	19730306	NL 1972-11992	19720902
	IT 968312	A	19740320	IT 1972-69805	19720902
	JP 48039477	A2	19730609	JP 1972-88608	19720904
PRAI	US 1971-177822	A	19710903		

GI For diagram(s), see printed CA Issue.

AB Eight title compds. (I, Rn = H, 2,4,6-Me3, or 2-MeO; R1 = Me, Pr, CH2Ph, or C6H4Me-o), useful as fungicides and plant growth regulators were prepared by reaction of R1CSNH2 MeCOCHClCO- NHC6H5-nRn in R1CN or MeCN. Thus, MeCSNH2 in MeCN reacted with MeCOCHClCONHPh for 20 min at 65-70° to give 95% I (Rn = H,R1 = Me).

IT **41470-23-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 41470-23-9 CAPLUS

CN 5-Thiazolecarboxamide, 4-methyl-N-phenyl-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1963:53202 CAPLUS

DN 58:53202

OREF 58:9040e-h

TI Compounds with potential antitubercular activity. IV. N-Substituted thioamides of 4-Oxazolecarboxylic acids

AU Sycheva, T. P.; Trupp, T. Kh.; Shchukina, M. N.

CS S. Ordzhonikidze All-Union Chem.-Pharm. Research Inst., Moscow

SO Zhurnal Obshchei Khimii (1962), 32, 2882-5
CODEN: ZOKHA4; ISSN: 0044-460X

DT Journal

LA Unavailable

GI For diagram(s), see printed CA Issue.

AB cf. CA 58, 1448h. Addition of 6.9 g. POCl3 to 3.81 g. 2-methyl-4-oxazolecarboxylic acid and 2.79 g. PhNH2 and heating 1 hr. at 130° gave after an aqueous treatment 8.9 g. 2-methyl-4-oxazolecarboxanilide (I, R = Me) (II), m. 133.5-5.5°. Similarly were prepared the following I (R given): PhCH2, m. 109.5-11°; Ph, m. 187-9°; p-MeC6H4, m. 180.5-2.5% Similarly were prepared: 2-benzyl-4-oxazolecarbomoypholide, m. 108-10% and the corresponding p-toluidide, m. 121-2°. II (1 g.) in 25 ml. pyridine heated with 2 g. P2S5 at 120-30° (bath temperature) 4 hrs. gave after an aqueous treatment and extraction of the precipitate with hot MeOH, 0.25 g. yellow 2-methyl-4-oxazolecarbothioanilide (III), m. 123-5°. Similarly were prepared the III analogs with following 2-substituents: PhCH2, m. 111-:3.5; Ph, m. 104-5°. Similarly were prepared 2-benzyl-4-oxazolecarbothio-p-toluidide, m. 91-3°, and the analogous thiomorpholide, m. 94-6°. 2-p-Tolyl-4-oxazolecarboxanilide and P2S5 in pyridine 10 hrs. at 120-30° gave after an aqueous treatment yellow 2-p-tolyl-4-thiazolecarbothioanilide, m. 147-9°. Et 2-p-toly14-oxazolecarboxylate in 2N NaOH 1 hr. gave the free acid, decomposed 229-30°. The replacement of the hetero O atom by S in the reaction with P2S5 was not observed for the other examples above.

IT **93323-65-0**, 4-Oxazolecarboxanilide, 2-benzyl- **98511-88-7**
, 4-Oxazolecarboxy-p-toluidide, 2-benzyl-

(preparation of)

RN 93323-65-0 CAPLUS

CN 4-Oxazolecarboxanilide, 2-benzyl- (7CI) (CA INDEX NAME)



RN 98511-88-7 CAPLUS

CN 4-Oxazolecarboxy-p-toluidide, 2-benzyl- (7CI) (CA INDEX NAME)



AN 2005:471944 CAPLUS
DN 143:26594
TI Preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette (ABC) transporters
IN Hadida Ruah, Sarah S.; Miller, Mark T.; Grootenhuis, Peter D. J.; Hamilton, Matthew
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005049018	A1	20050602	WO 2004-US38566	20041115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005130970	A1	20050616	US 2004-989218	20041115
PRAI US 2003-520355P	P	20031114		

OS MARPAT 143:26594
GI



I

AB A method of modulating ABC transporter activity comprises administration of title compds. [I; X = O, S; R1 = H, 3-8 membered (substituted) (unsatd.) (heterocyclic) ring; Z = bond, (substituted) (heteroatom-interrupted) alkylidene; R2 = halo, CF3, cyano, NO2, TqR; R3 = UmR'; R4 = VpCy1; m, p, q = 0, 1; U, V, T = (substituted) (heteroatom-interrupted) alkylidene; Cy1 = 3-8 membered (substituted) (unsatd.) (heterocyclic) ring; R = H, (substituted) aliphatyl; R' = R, (substituted) (unsatd.) (heterocyclic) ring]. Thus, 2-(4-methoxybenzyl)thiazole-4-carboxylic acid, C-[1-(3,4-dimethoxyphenyl)cyclopentyl]methylamine (preparation given), Et3N, and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate were stirred together for 16 h in MeCN to give 43.9% 2-(4-methoxybenzyl)thiazole-4-carboxylic acid [1-(3,4-dimethoxyphenyl)cyclopentyl]methylamide. Some I exhibit a relative modulating efficacy of >30%.

IT **852639-06-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters)

RN 852639-06-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(2,6-dichlorophenyl)methyl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l15
L15 HAS NO ANSWERS
L15 STR



VAR G1=O/S/N
VAR G2=1/5
VAR G3=32/35/38
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE

=> s l15 ful
FULL SEARCH INITIATED 13:14:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 65921 TO ITERATE

100.0% PROCESSED 65921 ITERATIONS 73 ANSWERS
SEARCH TIME: 00.00.02

L16 73 SEA SSS FUL L15

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	490.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.00

FILE 'CAPLUS' ENTERED AT 13:14:50 ON 25 MAY 2006

FILE COVERS 1907 - 25 May 2006 VOL 144 ISS 22
FILE LAST UPDATED: 24 May 2006 (20060524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l16
L17 12 L16

=> s l17 not l5
L18 10 L17 NOT L5

=> d bib abs hitstr 1-10

L18 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:735380 CAPLUS
DN 143:211902
TI Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
IN Chen, Bang-Chi; Zhao, Rulin; Wang, Bei
PA USA
SO U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005176965	A1	20050811	US 2005-49815	20050203
	WO 2005076990	A2	20050825	WO 2005-US3807	20050204
	WO 2005076990	A3	20051124		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-542465P P 20040206
US 2005-49815 A 20050203
OS MARPAT 143:211902
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is directed to processes for preparing 2-aminothiazole-5-carboxamides I [R1, R2 = H, alkyl, aryl, etc.; or R1 is taken together with R2, to form heteroaryl or heterocyclo; R3 = H, CN, haloalkyl, etc.; R4, R5 = H, alkyl, aryl, etc.; or R5 is taken together with R4, to form heteroaryl or heterocyclo] comprising reacting XCH2C(O)NR1R2 [R1, R2 as above; X = leaving group] with R4N(R5)C(S)N:C(R3)NR6R7 [R3-R5 as above; R6, R7 = alkyl, alkenyl, aryl, etc.; or R6 is taken together with R7, to form heteroaryl or heterocyclo]. Thus, reacting II with III (preparation of both reactants given) afforded (S)-IV. The exemplified compds. I have been tested and shown activity as kinase inhibitors, in particular, inhibitors of Src kinase, p38α/β enzymes, and/or TNF-α (no data given). The pharmaceutical composition for treating a kinase associated condition comprising the compound I is disclosed.

IT **745076-70-4P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors)

RN 745076-70-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-[(2-chlorophenyl)amino]-N-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1082034 CAPLUS
DN 142:56293
TI P-38 inhibitors
IN Dong, Qing; Pierre, Fabrice; Wang, Jianqiang
PA USA
SO U.S. Pat. Appl. Publ., 76 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004254236	A1	20041216	US 2004-860768	20040602
	AU 2004251668	A1	20050106	AU 2004-251668	20040602
	CA 2528438	AA	20050106	CA 2004-2528438	20040602
	WO 2005000298	A2	20050106	WO 2004-US17580	20040602
	WO 2005000298	A3	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1635824 A2 20060322 EP 2004-754233 20040602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-475662P P 20030603
US 2003-531541P P 20031219
WO 2004-US17580 W 20040602

OS MARPAT 142:56293

GI



I



II

AB 5-Membered heterocycle-based p38 kinase inhibitors I (R1 = H, Me, halogen, OH, lower alkyl, lower cycloalkyl, lower alkynyl, CF3, OMe, OCF3, CN, NH2, alkylamine, alkoxy; R2 = alkyl, substituted alkyl, lower cycloalkyl, halo, CF3, OCF3, alkoxy, alkylamine, sulfoxy, sulfone, amide, and n = 0, 1, or 2; R3 = H, alkyl, alkoxy, substituted alkyl, cycloalkyl, heteroaryl, heterocycle; Y = a single bond, C(O)NH, NHC(O), NHC(O)NH, SO2NH, NHSO2, C(O); B = a 5-membered heterocyclic ring system optionally substituted; Q = a single bond, O, S, alkylamine, SO, SO2, C(O), CO(O), C(O)NH, CH2; D = a monocyclic or bicyclic ring system) are prepared for the treatment of inflammatory and autoimmune diseases. Thus, to 3-amino-N-methoxy-4-methylbenzamide in CH2Cl2 was added benzoyl isothiocyanate, and N, N-diisopropylethylamine followed by treatment with hydrazine monohydrate to give II. II had an IC50 of less than 50 nM against p38α.

IT **808737-95-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of p-38 kinase inhibitors for the treatment of inflammatory and autoimmune diseases)

RN 808737-95-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



L18 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:878168 CAPLUS
DN 141:360665
TI Synergistic methods and compositions using insulin-like growth factor 1 receptor (IGF1R) inhibitors with additional kinase inhibitors for treating cancer
IN Carboni, Joan M.; Hurlburt, Warren W.; Gottardis, Marco M.; Lee, Francis Y.
PA USA
SO U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 676,214.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209930	A1	20041021	US 2004-814199	20040331
	CA 2500714	AA	20040415	CA 2003-2500714	20031001
	US 2004072760	A1	20040415	US 2003-677067	20031001
	AU 2003275364	A1	20040423	AU 2003-275364	20031001
	US 2004106605	A1	20040603	US 2003-676214	20031001
	EP 1551411	A2	20050713	EP 2003-759640	20031001
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006503867	T2	20060202	JP 2004-541997	20031001
	WO 2005094376	A2	20051013	WO 2005-US10820	20050330
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-415416P	P	20021002		
	US 2003-676214	A2	20031001		
	US 2003-677067	A2	20031001		
	WO 2003-US31091	W	20031001		
	US 2004-814199	A	20040331		

OS MARPAT 141:360665
AB Combination therapies using IGF1R inhibitors in combination with addnl. kinase inhibitors are described for the synergistic treatment of cancer.
IT **302963-66-2 302963-70-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IGF1 receptor inhibitors with addnl. kinase inhibitors for synergistic treatment of cancer)
RN 302963-66-2 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[5-[[3-(1H-imidazol-1-yl)propyl]amino]-2-nitrophenyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-70-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:701968 CAPLUS
DN 141:225499
TI Preparation of thiazolyl amide derivatives as p38 kinase inhibitors
IN Hynes, John; Wu, Hong; Leftheris, Katerina; Liu, Chunjian; Das, Jagabandhu; Moquin, Robert V.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004071440	A2	20040826	WO 2004-US3879	20040206
	WO 2004071440	A3	20041209		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004220233 A1 20041104 US 2004-773790 20040206
EP 1594854 A2 20051116 EP 2004-709122 20040206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2003-445410P P 20030206
WO 2004-US3879 W 20040206
OS MARPAT 141:225499
GI



I



II

AB Title compds. represented by the formula I [wherein A = Ph or pyridinyl; X = hydroxy, (un)substituted alkoxy, (alkylene)amino, amido, etc.; Y = CONR1 or NR1CO; R1 = H, (un)substituted cycloalkyl(alkyl), (hetero)aryl(alkyl), (heterocyclo)alkyl; R2 = H, alkyl, (hetero)cycloalkyl(alkyl), (hetero)aryl(alkyl); R3 = H, (halo)alkyl, alkoxy(alkyl), etc.; B = H, hydroxy, heterocycle, etc.; Z1 = (un)substituted alkyl, alkenyl, cyano, etc.; m = 0-3; n = 0-1; and enantiomers, diastereomers, pharmaceutically acceptable salts or solvates thereof] were prepared as kinase inhibitors (no data). For example, II was prepared in a multiple-step synthesis starting from Me 2-amino-5-thiazolylcarboxylate. Thus, I and their pharmaceutical compns. are useful for the treatment of p38 kinase-associated conditions (no data).

IT **745076-70-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolyl-5-amide derivs. as p38 kinase inhibitors)

RN 745076-70-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-[(2-chlorophenyl)amino]-N-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:220082 CAPLUS
DN 140:253556
TI Preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors
IN Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweyko, Arthur M. P.; Barrish, Joel C.; Wityak, John; Lombardo, Louis J.; Lee, Francis Y. F.
PA USA
SO U.S. Pat. Appl. Publ., 184 pp., Cont.-in-part of U.S. 6,596,746.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004054186	A1	20040318	US 2003-395503	20030324
	US 6596746	B1	20030722	US 2000-548929	20000413
	US 2004024208	A1	20040205	US 2003-378372	20030303
	US 6979694	B2	20051227		
	US 2004073026	A1	20040415	US 2003-378461	20030303
	US 2004077875	A1	20040422	US 2003-378373	20030303
	AU 2004223828	A1	20041007	AU 2004-223828	20040323
	CA 2519898	AA	20041007	CA 2004-2519898	20040323
	WO 2004085388	A2	20041007	WO 2004-US8827	20040323
	WO 2004085388	A3	20050630		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1610780	A2	20060104	EP 2004-758053	20040323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008782	A	20060328	BR 2004-8782	20040323
	CN 1764454	A	20060426	CN 2004-80007845	20040323
	US 2005261305	A1	20051124	US 2005-138793	20050525
	US 2005288303	A1	20051229	US 2005-138942	20050526
	NO 2005004359	A	20051019	NO 2005-4359	20050920
	US 2006079563	A1	20060413	US 2005-271626	20051110
PRAI	US 1999-129510P	P	19990415		
	US 2000-548929	A2	20000413		

	US 2003-378373	A1	20030303
	US 2003-395503	A	20030324
	WO 2004-US8827	W	20040323

OS MARPAT 140:253556

GI



I



II

AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day. The pharmaceutical composition comprising the title compds. is claimed.

IT **302963-66-2P 302963-70-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)

RN 302963-66-2 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[5-[[3-(1H-imidazol-1-yl)propyl]amino]-2-nitrophenyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-70-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



IT **302964-14-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)
RN 302964-14-3 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(5-fluoro-2-nitrophenyl)amino]- (9CI) (CA INDEX NAME)



L18 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:571107 CAPLUS
DN 139:133557
TI Preparation of phenylimino thiazolylidene thiazolidinones and other heterocyclic modulators of nuclear receptors with therapeutic uses
IN Martin, Richard; Flatt, Brenton Todd; Wang, Tie-Lin; Kahl, Jeffery Dean
PA X-Ceptor Therapeutics, Inc., USA
SO PCT Int. Appl., 481 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003060078	A2	20030724	WO 2002-US41224	20021220
	WO 2003060078	C2	20040219		
	WO 2003060078	C1	20040429		
	WO 2003060078	A3	20040624		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002367060	A1	20030730	AU 2002-367060	20021220
	US 2003212111	A1	20031113	US 2002-329668	20021220
	US 6696473	B2	20040224		
	EP 1465882	A2	20041013	EP 2002-806505	20021220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2004180942	A1	20040916	US 2003-717049	20031118
PRAI	US 2001-342720P	P	20011221		
	US 2002-329668	A1	20021220		
	WO 2002-US41224	W	20021220		

OS MARPAT 139:133557
GI



I



II

AB Phenylimino thiazolylidene thiazolidinones and other heterocyclic compds. (shown as I or its E/Z isomer; variables defined below; e.g. 3-benzyl-5-(3-methyl-3H-benzothiazol-2-ylidene)-2-thioxothiazolidin-4-one (shown as II)), compns. and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compds. are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. FXR agonism properties of >200 examples of I are tabulated. For I, X1, X2 and X3 = (i) or (ii) as follows: (i) X1, X2 and X3 = S, O or NR5; or (ii) X1 is -CR8:CR9- (R8 and R9 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.) and X2 and X3 = S, O or NR5. R1 is (un)substituted alkyl; R2 is (un)substituted aralkyl, aryl, alkenyl, alkyl, cycloalkyl, heteroaralkyl, or heterocyclylalkyl; R3 is (un)substituted heteroaryl, aryl, or aralkyl. A and G = (i), (ii) or (iii) as follows: (i) A and G = H, (un)substituted aryl, (un)substituted alkyl, (un)substituted alkoxycarbonyl, hydroxycarbonyl, and (un)substituted alkylcarbonyl; or (ii) A and G together form (un)substituted alkylene or azaalkylene; or (iii) A and G together form substituted butadienyl; D and E are each H, or together form a bond; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, .apprx.290 example prepns. are included.

IT **562825-59-6P**, 3-[[3-Benzyl-5-(1,3-dimethyl-1,3-dihydrobenzimidazol-2-ylidene)-4-oxothiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylimino thiazolylidene thiazolidinones and other heterocyclic modulators of nuclear receptors with therapeutic uses)

RN 562825-59-6 CAPLUS

CN Benzonitrile, 3-[[5-(1,3-dihydro-1,3-dimethyl-2H-benzimidazol-2-ylidene)-4-oxo-3-(phenylmethyl)-2-thiazolidinylidene]amino]-4-(ethylamino)- (9CI) (CA INDEX NAME)



L18 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:216934 CAPLUS

DN 138:238167

TI Preparation of aminocarbonyl-heterocyclic imines and their uses as agrochemical fungicides and insecticides
IN Niki, Toshio; Kikuchi, Takamasa; Kudo, Takao; Suzuki, Hiroyuki; Hayasaka, Fumio
PA Nissan Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 89 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2003081951	A2	20030319	JP 2002-184841	20020625
PRAI JP 2001-193575	A	20010626		

OS MARPAT 138:238167
GI



I

AB Title compds. I [A = (un)substituted hetero ring residue; X = halo, C1-6 (halo)alkyl, NO2, CN, CHO, etc.; n = 0-4; G = CH2CO2Me, etc.] and/or their agriculturally acceptable salts are prepared Thus, condensation of aniline with 2-(2-methoxycarbonylmethylphenylimino)-[1,3]oxathiol-5-carboxylic acid in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl salt in pyridine gave Me [2-(5-phenylcarbamoyl-[1,3]oxathiol-2-ylideneamino)phenyl]acetate, which showed ≥70% antifungal activity against Erysiphe graminis.
IT **501921-12-6P**
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic imines as agrochem. fungicides and insecticides)
RN 501921-12-6 CAPLUS
CN Benzeneacetic acid, 2-[[3-methyl-4-[(phenylamino)carbonyl]-2(3H)-thiazolylidene]amino]-, methyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:756524 CAPLUS
DN 133:321878
TI Preparation of cyclic protein tyrosine kinase inhibitors
IN Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweyko, Arthur M. P.; Barrish, Joel C.; Wityak, John
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 300 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000062778	A1	20001026	WO 2000-US9753	20000412
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2366932	AA	20001026	CA 2000-2366932	20000412
	AU 2000042338	A5	20001102	AU 2000-42338	20000412
	AU 779089	B2	20050106		
	EP 1169038	A1	20020109	EP 2000-922102	20000412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009721	A	20020213	BR 2000-9721	20000412
	TR 200102969	T2	20020821	TR 2001-200102969	20000412
	JP 2002542193	T2	20021210	JP 2000-611914	20000412
	NZ 513639	A	20040227	NZ 2000-513639	20000412
	RU 2260592	C2	20050920	RU 2001-130452	20000412
	ZA 2001007204	A	20021202	ZA 2001-7204	20010830
	NO 2001004970	A	20011210	NO 2001-4970	20011012
	US 2005261305	A1	20051124	US 2005-138793	20050525
	US 2005288303	A1	20051229	US 2005-138942	20050526
	US 2006079563	A1	20060413	US 2005-271626	20051110
PRAI	US 1999-129510P	P	19990415		
	WO 2000-US9753	W	20000412		
	US 2000-548929	A1	20000413		
	US 2003-378373	A1	20030303		

OS MARPAT 133:321878
GI



I



II

AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together

= O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day.

IT **302963-66-2P 302963-70-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic protein tyrosine kinase inhibitors)

RN 302963-66-2 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[5-[[3-(1H-imidazol-1-yl)propyl]amino]-2-nitrophenyl]amino]- (9CI) (CA INDEX NAME)



RN 302963-70-8 CAPLUS
CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



IT **302964-14-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclic protein tyrosine kinase inhibitors)

RN 302964-14-3 CAPLUS

CN 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(5-fluoro-2-nitrophenyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:440935 CAPLUS
DN 127:61966
TI Synthesis of new 2-iminothiazolines and their antifungal activities
AU Hahn, Hoh-Gyu; Nam, Kee Dal; Kim, Byung Sup; Cho, Kwang Yun
CS Organic Chemistry Lab., Korea Inst. Science and Technology, Seoul, 136-791, S. Korea
SO Han'guk Nonghwa Hakhoechi (1997), 40(2), 139-143
CODEN: JKACA7; ISSN: 0368-2897
PB Korean Society of Agricultural Chemistry and Biotechnology
DT Journal
LA Korean
AB New 2-iminothiazoline derivs. were prepared and tested for their biol. activity. For preparation of 2-iminothiazolines, primary amines were reacted with isothiocyanate, then with α-halo ketone derivs. Their antifungal activity was tested against six different plant diseases. A compound that has a phenylimino group at C-2, Me at C-3, phenylcarbamoylmethyl at C-4, and hydrogen at C-5 on the thiazoline skeleton was found to be most active.
IT **191466-62-3P 191466-63-4P 191466-64-5P**
191466-65-6P 191466-66-7P 191466-67-8P
191466-68-9P 191466-69-0P 191466-70-3P
191466-71-4P 191466-72-5P 191466-75-8P
191466-76-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of 2-iminothiazolines and their antifungal activities)
RN 191466-62-3 CAPLUS
CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,4-dimethyl-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-63-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3-methyl-N,4-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-64-5 CAPLUS
CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-N-(4-fluorophenyl)-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-65-6 CAPLUS
CN 5-Thiazolecarboxamide, N-(2,6-dichlorophenyl)-2-[(2,4-

dimethylphenyl)imino]-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-66-7 CAPLUS
CN 5-Thiazolecarboxamide, N-(2,5-dichlorophenyl)-2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-67-8 CAPLUS
CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-N-(2-methoxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-68-9 CAPLUS
CN 5-Thiazolecarboxamide, N-(4-cyanophenyl)-2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-69-0 CAPLUS
CN 5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,4-dimethyl-N-(4-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-70-3 CAPLUS
CN 5-Thiazolecarboxamide, 2-[(4-chloro-2-methylphenyl)imino]-2,3-dihydro-3,4-dimethyl-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-71-4 CAPLUS
CN 5-Thiazolecarboxamide, 2-[(4-chloro-2-methylphenyl)imino]-2,3-dihydro-3-methyl-N,4-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-72-5 CAPLUS
CN 5-Thiazolecarboxamide, 2-[(4-chloro-2-methylphenyl)imino]-N-(4-

chlorophenyl)-2,3-dihydro-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-75-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)imino]-2,3-dihydro-3,5-dimethyl-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 191466-76-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(4-chloro-2-methylphenyl)imino]-2,3-dihydro-3,5-dimethyl-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L18 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:65472 CAPLUS
DN 66:65472
TI 2-(2-Substituted-4-thiazolyl)benzimidazole derivatives
IN Tashika, Yoshio; Takanashi, Kumiko
SO Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 41020220	B4	19631125	JP	19631129

GI For diagram(s), see printed CA Issue.

AB Manufacture of I (R1 at C-5 or C-6), useful as anthelmintic sand insecticides, is described. In an example, 2.9 g. 5(or 6)-nitro-2-(α-oxobromoethyl)benzimidazole and 1.9 g. p-chlorophenylthiourea are dissolved in 50 cc. 2-ethoxyethanol, the whole refluxed 5-6 hrs., evaporated, H2O added to the residue, the mixture made alkaline with NH4OH, and the precipitated mass recrystd. from 50% EtOH to give 64% I (R1 = 5(or 6)-NO2, R2 = p-chloroanilino), m. 266°. Similarly prepared are the following I (R1 R2, and m.p. given): H, H, >300°; NO2, H, >300°; H, NH2, 261°; H, PhNH, 129.5-30°; Cl, NH2, 234-6°; Cl, NHMe, 274-6°; Cl, NHEt, 228.5-29°; Cl, NHPh, 129°; Cl, p-chloroanilino, 150-4°; Cl, p-bromoanilino, 268°; Cl, o-methoxyanilino, 283°; Cl, m-nitroanilino, 175-6°; NO2, NH2, >300°; NO2, NHMe, >300°; NO2, NHPh, 267°; NO2, m-nitroanilino, 206°; H, Me, 168-9°; Cl, Me, 169-70°; Me, Me, 270-2°.

IT **14521-72-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 14521-72-3 CAPLUS
CN Benzimidazole, 2-(2-o-anisidino-4-thiazolyl)-5-chloro- (8CI) (CA INDEX NAME)



```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
VAR G1=C/N
VAR G2=X/C/N/O
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE


=> d l11
L11 HAS NO ANSWERS
L11               SCR 1839


=> d his l15

     (FILE 'REGISTRY' ENTERED AT 12:27:32 ON 25 MAY 2006)
L15         7961 S L1 NOT L11 FUL

=> save l15
ENTER NAME OR (END):10775980/a
10775980/A IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list.  The name must:
  1. Begin with a letter,
  2. Have 1-12 characters,
  3. Contain only letters (A-Z) and numbers (0-9),
  4. End with /Q for a query (search profile,
     structure, or screen set), /A for an answer
     set, or /L for an L-number list.
  5. Not already be in use as a saved name,
  6. Not be END, SAV, SAVE, SAVED
  7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):sm775980/a
ANSWER SET L15 HAS BEEN SAVED AS 'SM775980/A'
```

IN 1,2,4-Triazin-3(2H)-one, 6-amino-5-(dimethylamino)- (9CI)
MF C5 H9 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 108 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Hydrazinecarboxylic acid, 2-(6-amino-3-methyl-1,2,4-triazin-5-yl)-, ethyl ester (9CI)
MF C7 H12 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 108 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1,2,4-Triazine-6-carboxylic acid, 5-amino-, ethyl ester (9CI)
MF C6 H8 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Scheme 7



Scheme 8



Scheme 9





Scheme 10



Scheme 11